Kuroki Norihiro, Abe Daisuke, Iwama Toru, Sugiyama Kazuhiro, Akashi Akiko, Hamabe Yuichi, Aonuma Kazutaka, Sato Akira
Department of Cardiology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Department of Cardiology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
J Cardiol. 2016 Nov;68(5):439-446. doi: 10.1016/j.jjcc.2015.10.014. Epub 2015 Nov 21.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can improve survival in patients with cardiogenic shock or cardiac arrest. We investigated the association between initial renal function and clinical outcome in patients undergoing VA-ECMO for cardiogenic shock and cardiac arrest.
This was a single-center, retrospective cohort study of 287 patients who underwent ECMO at our hospital from January 2005 to December 2014. We excluded 70 patients with non-cardiogenic events. The remaining 217 patients were divided into 2 groups according to initial estimated glomerular filtration rate (eGFR): Initial high eGFR (non-renal failure: non-RF) group: eGFR≥60ml/min/1.73m (n=73) and initial low eGFR (RF) group: eGFR<60ml/min/1.73m (n=144). Clinical outcome was defined as all-cause death at 30 days after extracorporeal life support.
VA-ECMO was begun in 87% of patients for cardiac arrest. The non-RF group was significantly younger (51.6 vs. 62.6 years), had lower body mass index (22.8 vs. 24.7kg/m), lower blood urea nitrogen (14.4 vs. 23.9mg/dl), and lower K (4.0 vs. 4.5mEq/l, all p<0.05) than the RF group. Incidence of all-cause death at 30 days was significantly lower in the non-RF than RF group (49% vs. 76%, p<0.0001). Initial low eGFR was an independent predictor of mortality after adjustment for multiple cofounders (OR: 4.08, 95% CI: 1.77-9.42, p<0.001). Kaplan-Meier curve showed better outcome in the non-RF versus RF group (p=0.0009).
An initial low eGFR may predict worse clinical outcome in patients undergoing VA-ECMO for cardiogenic shock and cardiac arrest.
静脉-动脉体外膜肺氧合(VA-ECMO)可提高心源性休克或心脏骤停患者的生存率。我们研究了因心源性休克和心脏骤停接受VA-ECMO治疗的患者初始肾功能与临床结局之间的关联。
这是一项单中心回顾性队列研究,研究对象为2005年1月至2014年12月在我院接受ECMO治疗的287例患者。我们排除了70例非心源性事件患者。其余217例患者根据初始估计肾小球滤过率(eGFR)分为两组:初始高eGFR(非肾衰竭:非RF)组:eGFR≥60ml/min/1.73m²(n = 73)和初始低eGFR(RF)组:eGFR<60ml/min/1.73m²(n = 144)。临床结局定义为体外生命支持30天后的全因死亡。
87%的患者因心脏骤停开始接受VA-ECMO治疗。与RF组相比,非RF组患者显著更年轻(51.6岁对62.6岁),体重指数更低(22.8对24.7kg/m²),血尿素氮更低(14.4对23.9mg/dl),血钾更低(4.0对4.5mEq/l,所有p<0.05)。非RF组30天全因死亡率显著低于RF组(49%对76%,p<0.0001)。在对多个混杂因素进行调整后,初始低eGFR是死亡率的独立预测因素(OR:4.08,95%CI:1.77 - 9.42,p<0.001)。Kaplan-Meier曲线显示非RF组的结局优于RF组(p = 0.0009)。
初始低eGFR可能预示因心源性休克和心脏骤停接受VA-ECMO治疗的患者临床结局更差。